ADC Therapeutics (ADCT) Aperçu de l'action
ADC Therapeutics SA propose une plateforme technologique de conjugués anticorps-médicaments (ADC) en Suisse et aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
ADCT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ADC Therapeutics SA Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.07 |
| Plus haut sur 52 semaines | US$4.98 |
| Plus bas sur 52 semaines | US$0.78 |
| Bêta | 1.85 |
| Variation sur 1 mois | 5.94% |
| Variation sur 3 mois | 1.90% |
| Variation sur 1 an | -67.67% |
| Variation sur 3 ans | 30.49% |
| Variation sur 5 ans | -96.29% |
| Évolution depuis l'introduction en bourse | -96.39% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 14
ADCT: LOTIS-5 Reset And LOTIS-7 Optionality Will Support Future Upside
Analysts have cut their average price targets for ADC Therapeutics, moving closer to the recent reductions to $5 and $2. They cite what they describe as underwhelming LOTIS-5 data, a tougher perceived benefit risk profile for Zynlonta, and higher regulatory uncertainty.Mise à jour du récit • Jun 26
ADCT: Reset Expectations On LOTIS-5 Will Support Future Upside Potential
Analysts have reduced their average price target on ADC Therapeutics from about $7.50 to roughly $5.00, reflecting concerns about Zynlonta's risk-benefit profile, modest LOTIS-5 trial outcomes, and increased regulatory risk highlighted in recent research updates. Analyst Commentary Recent research on ADC Therapeutics centers on how the LOTIS-5 trial reshapes expectations for Zynlonta, regulatory risk, and the company’s potential to create value through its broader pipeline.
Mise à jour du récit • Jun 11
ADCT: Future Earnings Potential Will Rely On Managing LOTIS-5 Safety Risks
Narrative Update: ADC Therapeutics Analyst Price Target Reset Analysts have cut their average price target for ADC Therapeutics to $2, from prior estimates closer to $6. This reflects concerns about Zynlonta's risk benefit profile and added regulatory risk following the LOTIS-5 trial results.Recent updates
Mise à jour du récit • Aug 14
ADCT: LOTIS-5 Reset And LOTIS-7 Optionality Will Support Future Upside
Analysts have cut their average price targets for ADC Therapeutics, moving closer to the recent reductions to $5 and $2. They cite what they describe as underwhelming LOTIS-5 data, a tougher perceived benefit risk profile for Zynlonta, and higher regulatory uncertainty.Mise à jour du récit • Jun 26
ADCT: Reset Expectations On LOTIS-5 Will Support Future Upside Potential
Analysts have reduced their average price target on ADC Therapeutics from about $7.50 to roughly $5.00, reflecting concerns about Zynlonta's risk-benefit profile, modest LOTIS-5 trial outcomes, and increased regulatory risk highlighted in recent research updates. Analyst Commentary Recent research on ADC Therapeutics centers on how the LOTIS-5 trial reshapes expectations for Zynlonta, regulatory risk, and the company’s potential to create value through its broader pipeline.Mise à jour du récit • Jun 11
ADCT: Future Earnings Potential Will Rely On Managing LOTIS-5 Safety Risks
Narrative Update: ADC Therapeutics Analyst Price Target Reset Analysts have cut their average price target for ADC Therapeutics to $2, from prior estimates closer to $6. This reflects concerns about Zynlonta's risk benefit profile and added regulatory risk following the LOTIS-5 trial results.Seeking Alpha • Jun 06
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy
Summary ADC Therapeutics is downgraded from 'Strong Buy' to 'Sell' due to safety concerns in ZYNLONTA's phase 3 LOTIS-5 trial. While ZYNLONTA + rituximab met the primary PFS endpoint, the regimen showed higher serious adverse events and Grade 5 TEAEs versus the comparator. Lack of overall survival benefit and increased withdrawals further undermine the risk-benefit profile for 2nd-line r/r DLBCL expansion. Strategic alternatives, including cost reductions, are under consideration, as regulatory and commercial prospects for ZYNLONTA become uncertain. Read the full article on Seeking AlphaMise à jour du récit • May 28
ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings Potential
Analysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.Article d’analyse • May 07
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report
It's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...Mise à jour du récit • May 03
ADCT: Updated Capital Plans And Refined Assumptions Will Support Future Upside Potential
Analysts have increased their price target on ADC Therapeutics by $1, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that they believe better align the valuation with current fundamentals and expectations. Analyst Commentary Despite the modest $1 lift in the price target, recent commentary around ADC Therapeutics still carries a cautious tone.Mise à jour du récit • Apr 19
ADCT: Refined Risk And Earnings Assumptions Will Support Future Upside Potential
Analysts raised their price target on ADC Therapeutics by $1, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively fine tune their outlook rather than overhaul it. Analyst Commentary Bearish analysts are treating the latest US$1 price target adjustment as a refinement rather than a signal of strong conviction, and their commentary leans cautious around execution, valuation and growth visibility.Mise à jour du récit • Apr 05
ADCT: Refreshed Revenue And Margin Assumptions Will Strengthen Future Earnings Power
Analysts have lifted their price target on ADC Therapeutics by $1, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary While the latest price target adjustment reflects refreshed modeling on discount rates, revenue assumptions, margins and future P/E, bearish analysts are still flagging several areas of concern that they see as reasons to stay cautious.Mise à jour du récit • Mar 21
ADCT: Higher Revenue Assumptions Will Support Stronger Future Earnings Power
Analysts have lifted their price target fair value for ADC Therapeutics from $5.00 to $6.00, citing updated assumptions for revenue growth, profit margins and future P/E that change their overall assessment of risk and return. Valuation Changes Fair Value: raised from $5.00 to $6.00 per share, indicating a higher assessed intrinsic value.Mise à jour du récit • Mar 04
ADCT: Higher Revenue Outlook And Richer P/E Multiple Will Support Upside
Analysts have trimmed their price target on ADC Therapeutics to $7.50 from $8.20, citing updated assumptions that combine higher projected revenue growth with lower expected profit margins and a higher future P/E multiple. Valuation Changes Fair Value: reduced from $8.20 to $7.50, a modest cut to the target level used in the model.Article d’analyse • Feb 05
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
ADC Therapeutics SA's ( NYSE:ADCT ) price-to-sales (or "P/S") ratio of 6.7x might make it look like a buy right now...Article d’analyse • Sep 30
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31%
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 31% in...Article d’analyse • May 27
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable
Key Insights ADC Therapeutics to hold its Annual General Meeting on 3rd of June CEO Ameet Mallik's total compensation...Article d’analyse • May 17
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results
ADC Therapeutics SA ( NYSE:ADCT ) just released its first-quarter report and things are looking bullish. Results...Article d’analyse • Apr 04
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 31% in the last thirty...
Nouveau récit • Apr 03
Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options
Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.Seeking Alpha • Mar 25
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Summary ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion. Despite a challenging competitive landscape, ADCT's current valuation and cash position make it a high-risk/high-reward investment, meriting a "Buy" sentiment with caution. Read the full article on Seeking AlphaArticle d’analyse • Mar 10
Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$1.47 ADC...Article d’analyse • Feb 12
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 26% in the last thirty...Seeking Alpha • Dec 12
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Summary Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034. Antibody-drug conjugate with monoclonal antibody directed CD-22 ADCT-602 is being explored in a phase 1/2 study for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Read the full article on Seeking AlphaArticle d’analyse • Nov 16
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
ADC Therapeutics SA ( NYSE:ADCT ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Jul 18
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Those holding ADC Therapeutics SA ( NYSE:ADCT ) shares would be relieved that the share price has rebounded 34% in the...Seeking Alpha • Jun 06
Limiting Concerns On ADC Therapeutics' Prospects
Summary ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors. Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues. ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia. ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway. Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating. Read the full article on Seeking AlphaArticle d’analyse • May 30
ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
The ADC Therapeutics SA ( NYSE:ADCT ) share price has fared very poorly over the last month, falling by a substantial...Article d’analyse • May 10
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
ADC Therapeutics SA ( NYSE:ADCT ) shareholders are probably feeling a little disappointed, since its shares fell 3.4...Seeking Alpha • Mar 19
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment. Read the full article on Seeking AlphaArticle d’analyse • Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
ADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Article d’analyse • Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 38% in...Seeking Alpha • Dec 29
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Summary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies. Read the full article on Seeking AlphaArticle d’analyse • Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$2.71 Current share...Seeking Alpha • Dec 01
ADC Therapeutics: Navigating A Swirling Drain
Summary ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024. Read the full article on Seeking AlphaRendement pour les actionnaires
| ADCT | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -21.3% | -5.2% | -0.9% |
| 1Y | -67.7% | 37.6% | 14.2% |
Rendement vs Industrie: ADCT a sous-performé le secteur US Biotechs qui a rapporté 37.6 % au cours de l'année écoulée.
Rendement vs marché: ADCT a sous-performé le marché US qui a rapporté 14.2 % au cours de l'année écoulée.
Volatilité des prix
| ADCT volatility | |
|---|---|
| ADCT Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: Le cours de l'action de ADCT a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ADCT ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2011 | 191 | Ameet Mallik | www.adctherapeutics.com |
ADC Therapeutics SA propose une plateforme technologique de conjugués anticorps-médicaments (ADC) en Suisse et aux États-Unis. Son produit phare, ZYNLONTA, un ADC dirigé contre le CD19, a reçu l'approbation accélérée de la Food and Drug Administration américaine, l'approbation conditionnelle de la Commission européenne et l'approbation conditionnelle de l'Administration nationale chinoise des produits médicaux pour le traitement du lymphome diffus à grandes cellules B (DLBCL) récidivant ou réfractaire après au moins deux lignes de traitement systémique. La société cherche également à poursuivre l'expansion de ZYNLONTA sur les marchés internationaux et dans les lignes antérieures de DLBCL et de lymphomes indolents, y compris le lymphome folliculaire (FL) et le lymphome de la zone marginale (MZL), en monothérapie et en association, par le biais de l'essai clinique de confirmation de phase 3 LOTIS-5 et de l'essai clinique de phase 1b LOTIS-7, ainsi que par le biais d'essais à l'initiative d'investigateurs.
ADC Therapeutics SA Résumé des fondamentaux
| ADCT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$136.60m |
| Bénéfices(TTM) | -US$96.91m |
| Recettes(TTM) | US$79.58m |
1.7x
Ratio P/S-1.4x
Ratio P/ELe site ADCT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ADCT compte de résultat (TTM) | |
|---|---|
| Recettes | US$79.58m |
| Coût des recettes | US$88.81m |
| Marge brute | -US$9.23m |
| Autres dépenses | US$87.68m |
| Les revenus | -US$96.91m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.76 |
| Marge brute | -11.59% |
| Marge bénéficiaire nette | -121.77% |
| Ratio dettes/capitaux propres | -191.6% |
Quelles ont été les performances à long terme de ADCT?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/13 05:12 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ADC Therapeutics SA est couverte par 21 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Naureen Quibria | Capital One Securities, Inc. |